

CD61

Rabbit Monoclonal antibody(Mab)

Catalog # AD80251

Product Information

Application	IHC-P
Primary Accession	P05106
Reactivity	Human
Host	Rabbit
Clonality	Monoclonal
Clone Names	623B2A1
Calculated MW	87058

Additional Information

Gene ID	3690
Gene Name	ITGB3
Other Names	Integrin beta-3, Platelet membrane glycoprotein IIIa, GPIIIa, CD61, ITGB3 (HGNC:6156), GP3A
Dilution	IHC-P~~Ready-to-use
Storage	Maintain refrigerated at 2-8°C.
Precautions	CD61 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information


Name	ITGB3 (HGNC:6156)
Synonyms	GP3A
Function	<p>Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha- V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-A-K-Q-A- G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen (PubMed:9111081). This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this</p>

binding is essential for NRG1-ERBB signaling (PubMed:[20682778](#)). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:[18441324](#)). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:[28302677](#)). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:[19578119](#)). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:[28873464](#)). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:[29030430](#)). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:[18635536](#), PubMed:[25398877](#)). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:[12807887](#)). In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:[31331973](#)). ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP (PubMed:[10640428](#)). Integrin ITGA2B:ITGB3 is also the receptor of the erythrocyte-specific ICAM4 ligand involved in heterotypic cell-cell adhesion between erythrocytes and activated platelets (PubMed:[12477717](#)).

Cellular Location Cell membrane; Single-pass type I membrane protein. Cell projection, lamellipodium membrane. Cell junction, focal adhesion. Postsynaptic cell membrane {ECO:0000250|UniProtKB:O54890}; Single-pass type I membrane protein {ECO:0000250|UniProtKB:O54890}. Synapse {ECO:0000250|UniProtKB:O54890}

Tissue Location Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis

Images



脾脏

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.